Indocyanine green acid form
As of the edition of 20 October 2026, Indocyanine green acid form is a small molecule: marketed, first approved in 1982 (US); no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Ic-Green
- First approved
- 1 January 1982 (US)
- Approvals on record
- 6 in 1 region
- Holder of the most recent approval
- Provepharm; 3 holders in all
- Registered trials
- 205, 27 stopped early
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Lungs and airways
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Novadaq Technologies holds a later exclusivity on its own new formulation or combination product, which ended in 2026; it does not protect the original drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 73 | 36 | 14 | 5 |
| Phase 1 | 49 | 29 | 11 | 3 |
| Phase 2 | 48 | 17 | 13 | 11 |
| Phase 3 | 13 | 6 | 4 | 2 |
| Phase 4 | 22 | 4 | 6 | 6 |
| All trials | 205 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novadaq Technologies | Later holder | 2018 to now |
| Renew Pharmaceuticals | Acquired holder | 2023 to now |
| Provepharm | Later holder | 2026 to now |
| Akorn | Earlier holder |